Navigation Links
Raven biotechnologies, inc. and Wyeth Pharmaceuticals Extend Evaluation Period of Selected Raven Antibodies
Date:12/6/2007

SOUTH SAN FRANCISCO, Calif., Dec. 6 /PRNewswire/ -- Raven biotechnologies, inc., a privately held company focused on the development of monoclonal antibody therapeutics (MAbs) for cancer, today announced that Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), has exercised an option to extend its evaluation of selected Raven MAb antibodies. As a result, Raven will receive an undisclosed milestone payment.

Under an agreement announced in January 2007, Wyeth has the option to obtain an exclusive license to develop and commercialize selected MAbs from Raven's portfolio of antibodies to a specified target.

The antibodies included in the agreement were discovered using Raven proprietary immunization technology and tumor-derived stem-cell lines and were screened to select antibodies that are active alone or in a conjugated form.

"We look forward to continuing our agreement with Wyeth, a company with a strong commitment to oncology research and development," said George F. Schreiner, M.D., Ph.D., Raven's Chief Executive Officer. "Raven has multiple anti-cancer antibody drug candidates in our pipeline, and collaborations such as this are a critical part of our strategy to rapidly advance the most promising candidates into the clinic."

About Raven

Raven biotechnologies, inc. (http://www.ravenbio.com) is a privately held biotechnology company focused on the development of monoclonal antibody therapeutics for treating cancer. Raven's lead product candidate, RAV12, targets adenocarcinomas and is in clinical development for the treatment of gastrointestinal and other cancers. Raven's discovery process simultaneously identifies cell-surface d
'/>"/>

SOURCE Raven biotechnologies, inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Positive Outcome of Drug-Drug Interaction Trial With Intravenous Iclaprim
2. Microchip Biotechnologies, Inc. Secures Exclusive License to Use New University of Alberta Technology for Developing Microfluidic Devices
3. Maven Biotechnologies, LLC to Present at BIOCOM Investor Conference
4. Millennium Biotechnologies, Inc. Launches SURGEX(TM) the First Scientifically Validated Sports Nutritional Product Created from the Medical Markets
5. Wyeth Sets Webcast and Conference Call for 2007 Third Quarter Earnings
6. Wyeth Announces $5 Billion Share Repurchase Program; Declares Increase in Common Stock Dividend
7. Wyeth Pharmaceuticals Acquires Haptogen Ltd. to Boost Biotechnology Drug Discovery
8. Wyeth Announces Election of New Principal Corporate Officer
9. Wyeth Declares Preferred Stock Dividend
10. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
11. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/18/2014)... (PRWEB) October 19, 2014 The ... (Short Acting, Intermediate Acting, Premixed), Modern Human Insulin ... Apidra, Levemir, NovoRapid, Novomix, Tresiba, Others) - Forecast ... major drivers, restraints, challenges, opportunities, current market trends, ... along with the estimates and forecasts of the ...
(Date:10/18/2014)... The Asian arthroscopic devices report defines and segments the ... revenue. The arthroscopic devices market in Asia is estimated ... CAGR of 6.5% from 2013 to 2018. , Browse ... to get an idea of the in-depth analysis provided. ... arthroscopic devices market in the same region, and is ...
(Date:10/18/2014)... The Asian Electronic Medical Record (EMR) market ... analysis and forecast of revenue. The electronic medical record market ... million by 2018, at a CAGR of 9.4% from 2013 ... Electronic Medical Record (EMR) market, to get an idea of ... the segmentation of the market in the same region, and ...
(Date:10/18/2014)... The report " Cloud Analytics ... Web; Speech; Machine; Video; Predictive Analytics: Global Advancements, ... & Analysis (2013 - 2018) ", defines and ... sub segments with an in-depth analysis and forecasting ... factors driving this market, various restraints, and opportunities ...
Breaking Biology Technology:Medical Human Insulin Market Is Expected to Reach $42 billion by 2019 - New Research Report by MarketsandMarkets 2Medical Human Insulin Market Is Expected to Reach $42 billion by 2019 - New Research Report by MarketsandMarkets 3Medical Human Insulin Market Is Expected to Reach $42 billion by 2019 - New Research Report by MarketsandMarkets 4Medical Human Insulin Market Is Expected to Reach $42 billion by 2019 - New Research Report by MarketsandMarkets 5The Asian arthroscopic devices market is estimated to grow to $712.3 million by 2018 - New Report by MicroMarket Monitor 2The Asian arthroscopic devices market is estimated to grow to $712.3 million by 2018 - New Report by MicroMarket Monitor 3The Asian arthroscopic devices market is estimated to grow to $712.3 million by 2018 - New Report by MicroMarket Monitor 4The Asian Electronic Medical Record (EMR) market is estimated to grow to $2,328.0 million by 2018 - New Report by MicroMarket Monitor 2The Asian Electronic Medical Record (EMR) market is estimated to grow to $2,328.0 million by 2018 - New Report by MicroMarket Monitor 3The Asian Electronic Medical Record (EMR) market is estimated to grow to $2,328.0 million by 2018 - New Report by MicroMarket Monitor 4The Asian Electronic Medical Record (EMR) market is estimated to grow to $2,328.0 million by 2018 - New Report by MicroMarket Monitor 5Cloud Analytics Market (by Cloud Business Intelligence & Predictive Analytics) Expected to Cross $16.52 Billion by 2018 - New Report by MarketsandMarkets 2Cloud Analytics Market (by Cloud Business Intelligence & Predictive Analytics) Expected to Cross $16.52 Billion by 2018 - New Report by MarketsandMarkets 3Cloud Analytics Market (by Cloud Business Intelligence & Predictive Analytics) Expected to Cross $16.52 Billion by 2018 - New Report by MarketsandMarkets 4Cloud Analytics Market (by Cloud Business Intelligence & Predictive Analytics) Expected to Cross $16.52 Billion by 2018 - New Report by MarketsandMarkets 5
... CITY, Calif., May 2, 2012 Genomic Health, Inc. ... (OncoMed) today announced a strategic alliance to use Next ... applied to the clinical development of OncoMed,s  novel antibody ... agreement, OncoMed will provide Genomic Health with breast, prostate, ...
... and leukocytes (white blood cells) move toward the sides ... method for treating sepsis, a systemic and often dangerous ... team of researchers at the Massachusetts Institute of Technology ... branchlike system of microfluidic channels, 20 micrometers (20 millionths ...
... Neurological Institute researchers Jorge Otero-Millan, Stephen Macknik, and Susana ... of Neuroscience in a compelling study into why ... St. Joseph,s Hospital and Medical Center in Phoenix. , ... bases of illusory motion in Akiyoshi Kitaoka,s striking visual ...
Cached Biology Technology:Genomic Health and OncoMed Announce Strategic Alliance for Biomarker Research and Discovery Using Next Generation Sequencing 2Genomic Health and OncoMed Announce Strategic Alliance for Biomarker Research and Discovery Using Next Generation Sequencing 3Genomic Health and OncoMed Announce Strategic Alliance for Biomarker Research and Discovery Using Next Generation Sequencing 4Barrow researchers unravel illusion 2
(Date:10/16/2014)... severe respiratory tract infections and worldwide claims the ... VIB and Ghent University have succeeded in developing ... virus infection. , Xavier Saelens (VIB/UGent): "We ... way for the development of a novel approach ... suffering in numerous small children and elderly people." ...
(Date:10/15/2014)... from strains of influenza virus increases with the latest ... complacent that the most substantial threats have been identified, ... arise when a new virus strain – against which ... in the human population. There have been five such ... which – the 1918 Spanish Flu – cost 50 ...
(Date:10/15/2014)... Researchers have linked increased resistance to bacterial pneumonia in ... sex hormone estrogen. , Females are naturally more resistant ... of scientists has shown that increased resistance to bacterial ... nitric oxide synthase 3 (NOS3). They also show that ... the female sex hormone estrogen. , The team, lead ...
Breaking Biology News(10 mins):New perspectives for development of an RSV vaccine 2Scientists 'must not become complacent' when assessing pandemic threat from flu viruses 2
... ongoing battle against secondhand tobacco smoke. They have pioneered the ... presence of secondhand smoke and even third-hand smoke. ... of a matchbox car, the device uses polymer films to ... then records the data on an SD memory card. The ...
... Environment Meeting of the U.S. Department of Energy Joint Genome ... Walnut Creek on March 26-28, 2013. The talks will focus ... and the environment. Keynote speeches will be delivered by Eric ... global analysis of oceanic plankton ecosystems" and Chris Voigt of ...
... and his team at the University of Queensland and the University ... test to discover just how fine a detail the archerfish could ... one of two letters an ,O, or a ,C, ... versions of both letters together and recorded which letter they spat ...
Cached Biology News:Scientists create new tools for battling secondhand smoke 2Scientists create new tools for battling secondhand smoke 3Archerfish get an eye test 2
... (ELISA) test kits are qualitative one-step kits ... of drugs and/or their metabolites in forensic ... use only. It is recommended that all ... method such as GC/MS. The simple ...
96 Well Base Plate...
... a recombinant human protein produced in E. coli ... RNase A type enzymes. The mode of ... in a 1:1 ratio. The enzyme has been ... and cell types. Addition of the ribonuclease inhibitor ...
... Inkjet Printer) is a revolutionary new ... Protein Macroarray Analysis, developed in conjunction ... strategy compliments established protocols in resolving ... proteins isoelectric point and apparent molecular ...
Biology Products: